Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

National Health Investors Inc. (NYSE:NHI) is a real estate investment trust that specializes in healthcare properties, particularly senior housing and medical office buildings.

It is set to report its Q3 2025 earnings on Nov. 6. Wall Street analysts expect the company to post EPS of $0.86, down from $1.03 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $83.72 million, up from $82.94 million a year earlier.

Don’t Miss:

• Meet Flippy: The AI Robot Helping Fast Food Brands Cut Tens of Billions in Labor Costs — And You Can Invest Early

• Accredited Investors Can Now Tap Into the $36 Trillion Home Equity Market — Without Buying a Single Property

The company’s stock traded at approximately $61.48 per share 10 years ago. If you had invested $10,000, you could have bought roughly 163 shares. Currently, shares trade at $76.09, meaning your investment’s value could have grown to $12,376 from stock price appreciation alone. However, National Health Investors also paid dividends during these 10 years.

National Health Investors’ dividend yield is currently 4.88%. Over the last 10 years, it has paid about $40.73 in dividends per share, which means you could have made $6,625 from dividends alone.

Summing up $12,376 and $6,625, we end up with the final value of your investment, which is $19,001. This is how much you could have made if you had invested $10,000 in National Health Investors stock 10 years ago. This means a total return of 90.01%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 297.70%.

Trending: Arrived Home’s Private Credit Fund’s has historically paid an annualized dividend yield of 8.1%*, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.

National Health Investors has a consensus rating of “Overweight” and a price target of $70.79 based on the ratings of 15 analysts. The price target implies nearly 7% potential downside from the current stock price.

The company on Aug. 6 announced its Q2 2025 earnings, posting FFO of $1.22, compared to the consensus estimate of $1.17, and revenues of $90.66 million, compared to the consensus of $87.69 million, as reported by Benzinga.

“We had another great quarter which exceeded our expectations. Given the strong quarterly results and continued good visibility into the second half of the year we are again raising our full year guidance and just announced an increase to our quarterly dividend,” said CEO Eric Mendelsohn.